
Trump administration's plan sounds good but faces severe operational obstacles
Trump administration's plan sounds good but faces severe operational obstacles
Aphena Pharma and Life Science Logistics announce new facilities as preparations for Covid-19 treatment evolve
Sponsors are hoping for $15 billion to address Covid-19 around the globe
The nonprofit generics maker for hospitals plans to enter consumer markets
Generics trade association is confronting a new, post-pandemic era
Deal is boosted by a $275-million investment from Blackstone Group
The land rush for specialty pharma business appears to be slowing among privately held specialty pharmacies
There are now 11 cell/gene therapies targeting Covid-19 in development
Ed Schoonveld’s compilation on pricing strategies gets updated for the 2020s
Company pitches a mfr-payer-provider-patient collaboration for drug pricing
Acquisitions jump BMS and Takeda into Top 10; Amgen and Gilead fall out
Guidance for companies starting out on the commercialization path
Guidance for companies starting out on the commercialization path
The PBMs’ new trend toward controlling the flow of funds for patient support is raising questions
Former J&J executive will be the organization’s third-ever leader
Milken Institute survey finds nearly 300 therapies and vaccines
Carving out CGTs for payment systems involving government intervention may be an answer
Revenue leakage in contracting and sales execution affects 95% of respondents
Acquisition of Cumberland Life Sciences boosts its client base and range of services
Now a Danaher Corp. asset, the former GE Healthcare Life Sciences business has been reshuffled
Newly initiated trials may prove value—but even then, supplies may be limited, and hoarding is already occurring
US list-price sales reached $510 billion in 2019
Copenhagen, Denmark tops Boyd Co.’s list with the highest annual operating costs
But: the growth number of companies is exceeding the growth of trials